Mabion SA MAB

GPW · Poland · Health Technology

PLN 7.80-0.06 (-0.76%)

Market closed· Oct 1, 2026, 3:02 PM UTC· PLN · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Mabion SA MAB

GPW · Poland · Health Technology

PLN 7.80-0.06 (-0.76%)

Market closed· Oct 1, 2026, 3:02 PM UTC· PLN · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-12.85% · 6MFull-screen chart

Open PLN 7.86High PLN 7.96Low PLN 7.72Close PLN 7.80Volume 14.25K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: PLN 7.86
Day range: PLN 7.72 – PLN 7.96
52-week range: PLN 6.70 – PLN 10.00
Volume: 14.25K
Market cap: PLN 127.04M
Next earnings date: 2026-11-17
Avg. volume (1Y): 37.72K

Performance

1 week

+0.26%

1 month

+1.43%

3 months

+7.14%

6 months

-8.88%

Year to date

+7.00%

1 year

-7.03%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: Poland
Exchange: GPW
Shares outstanding: 16.16M
Employees: 204.5
ISIN: PLMBION00016
Beta: 1.14

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceAug 26, 2026

Oddifact and Mabion Receive FDA Pre-IND Meeting Grant for RTX-NP (MabionCD20) in Immune Thrombocytopenia

FDA grants Type B pre-IND meeting, enabling critical alignment with the Agency on the development strategy for RTX-NPOddifact and Mabion aim to bring rituximab's well-established activity in ITP to formal FDA approval for the first time Paris, France – August 26, 2026 — Oddifact SAS, a French rare disease TechDev company, and Mabion S.A. (WSE: MAB), a Polish biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted a Type B pre-IND meeting for RTX-NP (Ma

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.